Related Experiment Videos
[Current treatment of tetanus patients in intensive therapy]
Minerva Anestesiologica
|October 1, 1979
Abstract:
A brief survey of recent criteria for evaluation of the seriousness of toxicity and infection in tetanus is followed by the examination of a series of cases of average severity. The method employed in their therapeutic management is described, and an account is given of its advantages and the possibility of complications. The mortality rate for the years 1974-1978 is also reported.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
Acta anaesthesiologica Scandinavica·2013
Bilateral adrenalectomy for Cushing's syndrome: a comparison between laparoscopy and open surgery.
Journal of endocrinological investigation·2004
[Postoperative patient controlled analgesia].
Minerva chirurgica·2003
Characterization of five tomato phospholipase D cDNAs: rapid and specific expression of LePLDbeta1 on elicitation with xylanase.
The Plant journal : for cell and molecular biology·2001
The hemostatic balance after plasma-exchange transfusion in myasthenia Gravis.
Minerva anestesiologica·2000
What should be the standard operation in chronic pancreatitis: Whipple or duodenum-preserving pancreatic head resection?
Annali italiani di chirurgia·2000
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026